Practical considerations for optimising homologous recombination repair mutation testing in patients with metastatic prostate cancer

Practical considerations for optimising homologous recombination repair mutation testing in patients with metastatic prostate cancer

Abstract Analysis of the genomic landscape of prostate cancer has identified different molecular subgroups with relevance for novel or existing targeted therapies. The recent approvals of the poly(ADP‐ribose) polymerase (PARP) inhibitors olaparib and rucaparib in the metastatic castration‐resistant...

Full description

Bibliographic Details
Main Authors: David Gonzalez, Joaquin Mateo, Albrecht Stenzinger, Federico Rojo, Michelle Shiller, Alexander W Wyatt, Frédérique Penault‐Llorca, Leonard G Gomella, Ros Eeles, Anders Bjartell
Format: Article
Language:English
Published: Wiley 2021-07-01
Series:The Journal of Pathology: Clinical Research
Subjects:
metastatic prostate cancer
molecular diagnostics
homologous recombination repair
poly(ADP‐ribose) polymerase inhibitors
mCRPC
Online Access:https://doi.org/10.1002/cjp2.203

Internet

https://doi.org/10.1002/cjp2.203

Similar Items